9,843 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,843 shares of the specialty pharmaceutical company’s stock, valued at approximately $544,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANIP. Sei Investments Co. boosted its position in shares of ANI Pharmaceuticals by 27.8% during the 2nd quarter. Sei Investments Co. now owns 14,473 shares of the specialty pharmaceutical company’s stock valued at $922,000 after acquiring an additional 3,152 shares in the last quarter. Marshall Wace LLP acquired a new position in ANI Pharmaceuticals in the second quarter worth about $253,000. AQR Capital Management LLC lifted its stake in ANI Pharmaceuticals by 44.8% during the second quarter. AQR Capital Management LLC now owns 17,527 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after purchasing an additional 5,419 shares during the period. Millennium Management LLC boosted its holdings in ANI Pharmaceuticals by 1,005.8% during the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of ANI Pharmaceuticals by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock valued at $605,000 after purchasing an additional 1,211 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ ANIP opened at $58.64 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The firm’s 50-day simple moving average is $56.61 and its 200 day simple moving average is $58.60. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -106.62 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.05 earnings per share. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several analyst reports. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $77.71.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,381 shares of company stock worth $2,441,556. Insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.